AIM
REGN icon

AIA Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

AIA Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$576K Buy
1,029
+235
+30% +$142K 0.13% 98
2020
Q2 		$495K Buy
794
+640
+416% +$363K 0.11% 79
2020
Q1 		$75K Hold
154
– – 0.02% 185
2019
Q4 		$58K Hold
154
– – 0.07% 182
2019
Q3 		$43K Buy
+154
New +$45.6K 0.04% 216

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIA Investment Management's REGN Position: Q3 2020 in Review

AIA Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 30% in Q3 2020, buying an estimated $142K and bringing the position to 1,029 shares worth $576K. The position accounts for 0.13% of the portfolio, ranked #98.

AIA Investment Management first reported a position in REGN in Q3 2019 and has held it in 5 quarters since. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • AIA Investment Management held 1,029 shares of Regeneron Pharmaceuticals worth $576K as of Q3 2020.
  • AIA Investment Management bought 235 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $142K.
  • Regeneron Pharmaceuticals made up 0.13% of AIA Investment Management's portfolio in Q3 2020, its #98 holding.
  • AIA Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2019 and has held it in 5 quarters since.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.